
TJX earnings beat, Revenue misses in Q2
Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter {{erl-8227||earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings...
Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter {{erl-8227||earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings...
The delegates noted the critical role played by US-India cooperation in addressing the COVID-19 pandemic and other global health challenges. They welcomed the partnership between Novavax and...
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
Novavax Inc (NASDAQ: NVAX) has submitted an application to the FDA for Emergency Use Authorization (EUA) for its protein-based COVID-19 vaccine as a homologous and heterologous booster in...
Novavax Inc. said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA...
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the...
By Peter Nurse Investing.com -- The main focus of the day will be the release of the latest U.S. consumer price data and the potential impact this has on Fed thinking. Elon Musk’s...
(Reuters) – U.S. vaccine maker Novavax slumped nearly 31% on Tuesday as falling demand for its COVID-19 shot from low- and middle-income nations led the company to cut its annual revenue...
BBQ Holdings Inc (NASDAQ:BBQ) +46%; entered into a definitive merger agreement under which MTY would acquire all of the issued and outstanding common shares of BBQ Holdings for cash...
By Senad Karaahmetovic Shares of Novavax (NASDAQ:NVAX) crashed almost 33% in premarket Tuesday trading after the company cut its full-year revenue guidance. For the second quarter,...
By Peter Nurse Investing.com -- U.S. stocks are seen opening in a subdued fashion Tuesday, with investors awaiting more corporate earnings results as well as the release of a key...
By Oliver Gray Investing.com - U.S. stock futures were slightly higher during Monday’s evening deals, after major benchmark averages finished mixed during regular trading as market...
GoodRx Holdings, Inc. (GDRX) +34%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.Lemonade (LMND) +13%; reported Q2 EPS of ($1.10), $0.23...
Novavax (NASDAQ:NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02...
By Geoffrey Smith Investing.com -- U.S. stocks are set to open higher after the Democrats' long-awaited and much-diluted tax and spending bill finally cleared the Senate at the weekend. A...
The daily average for new U.S. cases may have started to decline based on official numbers, but it's unclear at this time if the trend is real as so many people are testing at home and the...
Novavax Inc (NASDAQ: NVAX) has initiated its Phase 2b/3 Hummingbird trial to evaluate the safety, effectiveness, and efficacy of two doses of the Novavax COVID-19 vaccine in children aged...
LONDON (Reuters) -The European Medicines Agency (EMA) is recommending Novavax’s COVID-19 vaccine carry a warning of two inflammatory conditions of the heart, based on a small number of...
Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval in Japan for adolescents aged 12 through 17. Novavax has...
Novavax Inc. said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old....
The US Centers for Disease Control and Prevention (CDC) has endorsed recommendation that Novavax's Covid-19 vaccine be used as another primary series option for adults aged 18 years and...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Advisory Committee Recommends Novavax's COVID-19 Vaccine For Adults The U.S. Centers for...
The U.S. Centers for Disease Control and Prevention's (CDC) advisory committee recommended using Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine as a two-dose primary series for individuals...
The Centers for Disease Control and Prevention authorized the Novavax [s:nvax] vaccine late Tuesday, lifting the final regulatory hurdle for the nation's fourth vaccine, which is based on...
The CDC approved Novavax's COVID vaccine on Tuesday, and investors sent Novavax's stock up 11.5%
CDC officials said between 26 million and 37 million adults haven’t had a single dose -- the population that Novavax, for now, will be targeting.
By Mrinalika Roy (Reuters) -Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday voted unanimously to recommend use of Novavax Inc’s COVID-19 vaccine for...
Shares of Novavax Inc. jumped 11.9% in trading on Tuesday after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of the company's...
Novavax uses different technology than Pfizer and Moderna. U.S. health officials hope Novavax's shots might convince skeptics to get vaccinated.
The newly authorized shot will become widely available if the Centers for Disease Control and Prevention follows the advice of its advisers and recommends the vaccine.
An advisory panel to the Centers for Disease Control and Prevention will meet later Tuesday to discuss the Novavax [s:nvax] vaccine that recently won authorization from the Food and Drug...
The USFDA approval makes SII - the first Indian vaccine maker to export vaccines to the US market, a testimony to the company's abilities to produce vaccines under stringent quality...
The European Medicines Agency identified severe allergic reactions as potential side effects of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine. A few cases of anaphylaxis have been reported...
Coronavirus Update: Protein-based vaccine’s OK fails to boost Novavax stock
U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novavax Receives Much Awaited FDA Nod For Protein-Based COVID-19 Vaccine The FDA granted...
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the US -- and one that's already available in Europe and multiple other...
Novavax, Inc. (NASDAQ: NVAX) is on the verge of launching its COVID-19 vaccine for individuals 18 years and above. The U.S. Food and Drug Administration (FDA) granted emergency use...
U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand...
Novavax says its vaccine prompted 'broad immune responses' against all COVID variants, including BA.5, in clinical data.
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the Novavax Covid-19 vaccine in individuals 18 years of age and older
By Vlad Schepkov It’s official! The U.S. Food and Drug Administration (FDA) has at last given its affirmative nod to what is now the 4th officially approved COVID-19 vaccine in the United...
By Liz Moyer Investing.com -- U.S. stocks wobbled on Wednesday after a higher-than-expected reading on June inflation. Here are the midday movers for July 13: Twitter Inc (NYSE:TWTR)...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.